This Spanish antiviral has caused a stir due to its efficacy in eliminating almost 100 percent of the SARS-Cov-2 viral load. This has been shown by the different scientific studies that give hope to the world in this pandemic
Great impact has been generated by the discovery of this Spanish antiviral called Plitidepsin, scientists have discovered that by consuming it it can reduce almost 100% of the viral load of covid-19. Studies have shown that it has a direct impact, it is an effective antiviral to counteract the coronavirus.
The antiviral Plitidepsin has worked to eliminate almost 100% of the viral load, and the Spanish laboratory PharmaMar is already analyzing the start of phase 3 trials. So far the first trials have been a complete success.
The first studies of the antiviral of the Spanish company were carried out in laboratories in the United States and France. This research was published in the journal Science demonstrates that plitidepsin reduces almost the entire viral load of the virus.
So far Plitidepsin is one of the most powerful drugs on the market to counteract covid-19, there is hope that little by little the infected will heal, but at the same time it is reported that this drug is found in trials of the third phase.
It should be noted that the tests were conducted on animals and the drug is known to be 100 times more potent than the current one. The experiments have been "in vitro and" in vivo "it is not only effective as an antitumor, but it also turned out to be effective as an antiviral.
"Promising antiviral efficacy and toxicity profile have been demonstrated," they reported in the journal Science. This drug has limited toxicity, "the antiviral activity of plitidepsin against SARS-CoV-2 is produced by inhibiting a known target (eEF1A)".
According to studies, it has been shown that treating animals infected with SARS-CoV-2 significantly reduced the viral load in their lungs. The researchers note in their report that although toxicity is a concern in any antiviral targeting a human cell protein, the safety profile of plitidepsin is well established in humans.
Nevan Krogan, director of the Institute for Quantitative Biosciences (QBI) at the University of California in San Francisco, joined forces with researchers from the University of California in an effort to join forces to combat covid-19. , the Gladstone Institute, the Icahn School of Medicine at Mount Sinai, the Pasteur Institute, and the Howard Hughes Medical Institute. They are currently working to find the definitive cure and combat covid-19.